Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

RCT (n=1069) reported longer progression-free survival with lenvatinib plus pembrolizumab (median, 23.9 vs. 9.2 months; HR 0.39; 95%, 0.32 to 0.49; P<0.001) and lenvatinib plus everolimus (median, 14.7 vs. 9.2 months; 0.65; 0.53 to 0.80; P<0.001) vs sunitinib.

New England Journal of Medicine